Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Clinical trial NCT05211336 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05211336
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

Start date: 2022-04-19
Primary completion: 2024-06-01
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.